Increased expression of mRNA encoding RANTES and MCP-3 in the bronchial mucosa in atopic asthma

European Respiratory Journal

Volumn 9, Issue 12, 1996, Pages 2454-2460

  Powell, N ^a   Humbert, M ^a   Durham, S R ^a   Assoufi, B ^a   Kay, A B ^a   Corrigan, C J ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

asthma; atopy; chemokines; eosinophils

Indexed keywords

CHEMOKINE; MESSENGER RNA;

ADULT; ARTICLE; ASTHMA; ATOPY; BRONCHUS MUCOSA; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0029854993     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09122454     Document Type: Article

References (33)

1. Djukanovic R, Wilson JW, Britten KM, et al. Quantification of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects. Am Rev Respir Dis 1990; 142: 863-871.
2. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-1039.
3. Bradley BL, Azzawi M, Jacobson M, et al Eosinophils, T-lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects, and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 8: 661-674.
4. Corrigan CJ, Kay AB. T-cells and eosinophils in the pathogenesis of asthma. Immunology Today 1992; 13: 501-507.
5. Clutterbuck EJ, Hirst EMA, Sanderson CJ. Human inter-leukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 1989; 73: 1504-1512.
6. Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant human granulocyte/macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986; 78: 1220-1228.
7. Rothenburg ME, Owen WF, Silberstein DS, et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3. J Clin Invest 1988; 81: 1986-1992.
8. Rothenburg ME, Peterson J, Stevens RL, et al. IL-5 dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143: 2311-2316.
9. Kameyoshi Y, Dörschner A, Mallet AI, Christophers E, Schröder J-M. Cytokine RANTES released by thrombin-stimulated platelets is a potent chemoattractant for human eosinophils. J Exp Med 1992; 176: 587-592.
10. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein-1α induces the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992; 176: 1489-1495.
11. Alam R, Stafford S, Forsythe P, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993; 150: 3442-3447.
12. Dahinden CA, Geiser T, Brunner T, et al. Monocyte chemotactic protein-3 is a most effective basophil- and eosinophil-active chemokine. J Exp Med 1994; 179: 751-756.
13. Meurer R, Van Riper G, Feeney W, et al. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, or human interleukin-8. J Exp Med 1993; 178: 1913-1921.
14. Ponath PD, Qin S, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin. J Clin Invest 1996; 97: 604-612.
15. Beck L, Stellate C, Dalke S, et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects (Abstract). J Allergy Clin Immunol 1996; 97: 425.
16. Malick A, Stafford S, Li H, Forsythe P, Alam R, Galveston TX. The lung inflammatory responses to CC chemokines, MCP-1, MCP-3, MIP-1α and RANTES, in mice challenged in vivo (Abstract). J Allergy Clin Immunol 1996; 97: 404.
17. Humbert M, Grant JA, Taborda-Barata L, et al. High affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996; 153: 1931-1937.
18. Doi S, Gemou-Engesaeth V, Kay AB, Corrigan CJ. Polymerase chain reaction quantification of cytokine messenger RNA expression in peripheral blood mononuclear cells of patients with acute exacerbations of asthma: effect of glucocorticoid therapy. Clin Exp Allergy 1994; 24: 854-867.
19. Schall TJ, Jongstra J, Dyer BJ, et al. A human T-cell-specific molecule is a member of a new gene family. J Immunol 1988; 141: 1018-1025.
20. Minty A, Chalon P, Guillemot C. Molecular cloning of the MCP-3 chemokine gene and regulation of its expression. Eur Cytokine Netw 1993; 4: 99-110.
21. Ying S, Taborda-Barata L, Meng Q, Humbert M, Kay AB. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T-cell, and macrophage recruitment. J Exp Med 1995; 181: 2153-2159.
22. Kimata H, Yoshida A, Ishioka K, Fujimoto M, Lindley I, Furusho K. RANTES and macrophage inflammatory protein-1α selectively enhance immunoglobulin (IgE) and IgG4 production by human B-cells. J Exp Med 1996; 183: 2397-2402.
23. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T-lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671.
24. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Monocyte chemotactic proteins, MCP-1, MCP-2 and MCP-3, are major attractants for human CD4+ and CD8+ T-lymphocytes. FASEB J 1994; 8: 1055-1060.
25. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic-protein-1 (MCP-1) -2 and -3 are chemotactic for human T-lymphocytes. J Clin Invest 1995; 95: 1370-1376.
26. Kuna P, Reddigari T, Schall TJ, Rucinski D, Viksman MY, Kaplan AP. RANTES, a monocyte and T-lyraphocyte chemotactic cytokine, releases histamine from human basophils. J Immunol 1992; 149: 636-642.
27. Rajakulasingam K, Hamid Q, O'Brien F, et al. Increases in RANTES mRNA and protein in the nasal secretions in hay fever patients after allergen challenge (Abstract). J Allergy Clin Immunol 1996; 97: 193.
28. Devergne O, Marfaing-Koda A, Schall T, et al. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med 1994; 179: 1689-1694.
29. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The chemokine, eotaxin, activates guineapig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993; 197: 1167-1172.
30. Schall TJ, Lu LH, Gillett N, Amento EP. RANTES/sis cytokine gene expression in rheumatoid synovium as analysed by in situ hybridisation (Abstract). Arthritis Rheum 1991; 34: S117.
31. Ying S, Meng Q, Taborda-Barata LM, et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Ear J Immunol 1996; 26: 70-76.
32. Stellato C, Beck LA, Gorgone GA, et al. Expression of the chemokine RANTES by a human bronchial epithelial cell line. J Immunol 1995; 155: 410-418.
33. Wang JH, Devalia JL, Xia C, Sapsford RJ, Davies RJ. Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Am J Respir Cell Mol Biol 1996; 14: 27-35.